Atherosclerosis: a unifying disorder with diverse manifestations

Area of Science:

• Cardiovascular Medicine
• Hematology

Background:

• Cardiovascular disease is the leading cause of death in the U.S., with over 60 million Americans affected.
• Atherosclerosis underlies numerous cardiovascular diseases, leading to significant morbidity, mortality, and an estimated $95 billion in annual costs for coronary heart disease.
• Patients with atherosclerosis in one vascular bed face a high risk of ischemic events in other areas, highlighting its systemic nature.

Purpose of the Study:

• To review the epidemiology, costs, and comorbidities of atherosclerosis.
• To examine the role of newer antiplatelet agents in managing atherosclerosis and preventing atherothrombosis.
• To emphasize the importance of recognizing atherosclerosis as a generalized disease process.

Main Methods:

• Literature review of epidemiological data, cost analyses, and clinical studies.
• Analysis of the role of platelets in atherothrombosis and ischemic events.
• Evaluation of current antiplatelet therapies, including thienopyridines like clopidogrel.

Main Results:

• Atherosclerosis is a prevalent condition associated with substantial healthcare costs and significant patient risk.
• Platelets are central to atherothrombosis, mediating arterial thrombosis and acute ischemic events.
• Current antiplatelet therapy is underutilized, with only one-third to one-half of eligible patients receiving treatment.

Conclusions:

• Advances in antiplatelet therapy present opportunities to reduce atherosclerosis-related morbidity and mortality.
• Therapeutic strategies should address atherosclerosis as a systemic disease, aiming to prevent ischemic events across multiple vascular beds.
• Increased utilization of effective antiplatelet agents is crucial for managing patients at risk.